The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Once-Weekly Semaglutide in Adolescents with Obesity
Open accessAbstract
BACKGROUND: A once-weekly, 2.4-mg dose of subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist, is used to treat obesity in adults, but assessment of the drug in adolescents has been lacking. METHODS: In this double-blind, parallel-group, randomized, placebo-controlled trial, we enrolled adolescents (12 to <18 years of age) with obesity (a body-mass index [BMI] in the 95th percentile or higher) or with overweight (a BMI in the 85th percentile or higher) and at least one weight-related coexisting condition. Participants were randomly assigned in a 2:1 ratio to receive once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo for 68 weeks, plus lifestyle intervention. The primary end point was the percentage change in BMI from baseline to week 68; the secondary confirmatory end point was weight loss of at least 5% at week 68. RESULTS: A total of 201 participants underwent randomization, and 180 (90%) completed treatment. All but one of the participants had obesity. The mean change in BMI from baseline to week 68 was -16.1% with semaglutide and 0.6% with placebo (estimated difference, -16.7 percentage points; 95% confidence interval [CI], -20.3 to -13.2; P<0.001). At week 68, a total of 95 of 131 participants (73%) in the semaglutide group had weight loss of 5% or more, as compared with 11 of 62 participants (18%) in the placebo group (estimated odds ratio, 14.0; 95% CI, 6.3 to 31.0; P<0.001). Reductions in body weight and improvement with respect to cardiometabolic risk factors (waist circumference and levels of glycated hemoglobin, lipids [except high-density lipoprotein cholesterol], and alanine aminotransferase) were greater with semaglutide than with placebo. The incidence of gastrointestinal adverse events was greater with semaglutide than with placebo (62% vs. 42%). Five participants (4%) in the semaglutide group and no participants in the placebo group had cholelithiasis. Serious adverse events were reported in 15 of 133 participants (11%) in the semaglutide group and in 6 of 67 participants (9%) in the placebo group. CONCLUSIONS: Among adolescents with obesity, once-weekly treatment with a 2.4-mg dose of semaglutide plus lifestyle intervention resulted in a greater reduction in BMI than lifestyle intervention alone. (Funded by Novo Nordisk; STEP TEENS ClinicalTrials.gov number, NCT04102189.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Approved by FDA/EMA from age 12.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [113]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“73% achieved ≥ 5% weight loss and with significant amelioration of CVD factors (e.g. waist circumference, ALT and HbA1c) and no adverse impact on pubertal development and bone health [113].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [113]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar efficacy was achieved with once-weekly subcutaneous injections of 2.4 mg semaglutide in the STEP Teens trial among adolescents aged 12–18 years [80]”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [80]
The cited source says what the claim attributes to it.
In the citing paper
“In the STEP TEENS trial, adolescents achieved a − 16.1% mean BMI reduction vs. + 0.6% in the placebo group.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [113]
In the citing paper
“Similar efficacy was achieved with 2.4 mg once weekly injections in adolescents with comorbidities (STEP Teens) and with a high dose (50 mg once daily) of the oral formulation of semaglutide in adults (OASIS-1) [24, 25].”
From Recent advances in peptide-based therapies for obesity and type 2 diabetes (2024) · cites this paper as [24]
In the citing paper
“However, weight loss was less amongst obese individuals with T2DM (eg 9.6% weight loss with the 2.4 mg once weekly injected semaglutide in STEP-2) for likely reasons described above [17, 24, 25].”
From Recent advances in peptide-based therapies for obesity and type 2 diabetes (2024) · cites this paper as [24]
In the citing paper
“the main trials for which data have been published (STEP 1 through STEP 5, STEP 8, and STEP TEENS) did not include participants who reported having symptoms of major depressive disorder within 2 years before screening, which limits their ability to assess psychiatric adverse events in people with a recent history of depression [3,4,93,94,95,96,97].”
From What Is Food Noise? A Conceptual Model of Food Cue Reactivity (2023) · cites this paper as [97]
In the citing paper
“STEP TEENS studied semaglutide 2.4 mg in adolescents living with obesity and reported that semaglutide versus placebo resulted in a 17.7-kg weight loss over 68 weeks (Table 3B).76”
From Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists (2024) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Bray, G. A., Kim, K. K., Wilding, J. P. H., & on behalf of the World Obesity Federation (2017) · Obesity Reviews · doi:10.1111/obr.12551 · Cited by 1,612
Overweight in Children and Adolescents
Daniels, S. R., Arnett, D. K., Eckel, R. H., Gidding, S. S., Hayman, L. L., Kumanyika, S., Robinson, T. N., Scott, B. J., Jeor, S. S., & Williams, C. L. (2005) · Circulation · doi:10.1161/01.cir.0000161369.71722.10 · Cited by 1,543
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Self-citationStyne, D. M., Arslanian, S. A., Connor, E. L., Farooqi, I. S., Murad, M. H., Silverstein, J. H., & Yanovski, J. A. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2573 · Cited by 1,375
Self-citationWilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128
Posner, K., Oquendo, M. A., Gould, M., Stanley, B., & Davies, M. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1035 · Cited by 1,025
Kelly, A. S., Barlow, S. E., Rao, G., Inge, T. H., Hayman, L. L., Steinberger, J., Urbina, E. M., Ewing, L. J., & Daniels, S. R. (2013) · Circulation · doi:10.1161/cir.0b013e3182a5cfb3 · Cited by 980
Self-citationTwo-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
Screening for Obesity in Children and Adolescents
US Preventive Services Task Force, Grossman, D. C., Bibbins-Domingo, K. B., Curry, S. J., Barry, M. J., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., Krist, A. H., et al. (2017) · JAMA · doi:10.1001/jama.2017.6803 · Cited by 837
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916038 · Cited by 723
Self-citationChildhood Cardiovascular Risk Factors and Adult Cardiovascular Events
Jacobs, D. R., Woo, J. G., Sinaiko, A. R., Daniels, S. R., Ikonen, J., Juonala, M., Kartiosuo, N., Lehtimäki, T. J., Magnussen, C. G., Viikari, J. S. A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2109191 · Cited by 652
Screening for Obesity and Intervention for Weight Management in Children and Adolescents
O’Connor, E., Evans, C. V., Burda, B. U., Walsh, E. S., Eder, M. L., & Lozano, P. (2017) · JAMA · doi:10.1001/jama.2017.0332 · Cited by 515
Friedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14280 · Cited by 427
Treatment of Pediatric Obesity: A Systematic Review and Meta-Analysis of Randomized Trials
McGovern, L. B., Johnson, J. N., Paulo, R., Hettinger, A., Singhal, V., Kamath, C. C., Erwin, P. J., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2409 · Cited by 382
Ells, L. J., Rees, K., Brown, T. J., Mead, E., Al-Khudairy, L., Azevedo, L. B., McGeechan, G., Baur, L. A., Loveman, E., Clements, H., et al. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0230-y · Cited by 256
Assessing Weight‐Related Quality of Life in Adolescents
Kolotkin, R. L., Zeller, M. H., Modi, A. C., Samsa, G. P., Quinlan, N. P., Yanovski, J. A., Bell, S. K., Maahs, D. M., de Serna, D. G., & Roehrig, H. R. (2006) · Obesity · doi:10.1038/oby.2006.59 · Cited by 210
Phentermine/Topiramate for the Treatment of Adolescent Obesity
Kelly, A. S., Bensignor, M. O., Hsia, D. S., Shoemaker, A. H., Shih, W., Peterson, C., & Varghese, S. T. (2022) · NEJM Evidence · doi:10.1056/evidoa2200014 · Cited by 169
Self-citationChild Obesity and Mental Health
Small, L., & Aplasca, A. (2016) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2015.11.008 · Cited by 113
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
Lyseng-Williamson, K. A. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00826-0 · Cited by 87
Weghuber, D., Forslund, A. H., Ahlström, H. K., Alderborn, A., Bergström, K., Brunner, S. M., Cadamuro, J., Ciba, I., Dahlbom, M., Heu, V., et al. (2020) · Pediatric Obesity · doi:10.1111/ijpo.12624 · Cited by 79
Self-citationWharton, S., Astrup, A., Endahl, L., Lean, M. E. J., Satylganova, A., Skovgaard, D., Wadden, T. A., & Wilding, J. P. H. (2021) · International Journal of Obesity · doi:10.1038/s41366-020-00733-x · Cited by 58
Medications for the treatment of obesity in adolescents
Woodard, K. T., Louque, L., & Hsia, D. S. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820918789 · Cited by 56
Missing data in clinical trials for weight management.
McEvoy, B. W. (2016) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2015.1094814 · Cited by 27
Treatment of children and adolescents who are overweight or obese
Figlia-Peck, S. D., Feinstein, R., & Fisher, M. (2020) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2020.100871 · Cited by 20
Flagged first, then by citations
Cited by
Sorted by citations
Gao, C. A., Howard, F. M., Markov, N. S., Dyer, E. C., Ramesh, S., Luo, Y., & Pearson, A. T. (2023) · npj Digital Medicine · doi:10.1038/s41746-023-00819-6 · Cited by 1,099
Lister, N. B., Baur, L. A., Felix, J. F., Hill, A. J., Marcus, C., Reinehr, T., Summerbell, C., & Wabitsch, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00435-4 · Cited by 596
Kerr, J. A., Patton, G. C., Cini, K. I., Abate, Y. H., Abbas, N., Magied, A. H. A. A. A., ElHafeez, S. A., Abd-Elsalam, S. M., Abdollahi, A., Abdoun, M., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00397-6 · Cited by 603
Gao, C. A., Howard, F. M., Markov, N. S., Dyer, E. C., Ramesh, S., Luo, Y., & Pearson, A. T. (2022) · doi:10.1101/2022.12.23.521610 · Cited by 1,099
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
Metadata
- Authors
- Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., Kelly, A. S., Mastrandrea, L. D., Sørrig, R., & Arslanian, S.
- Affiliations
- University of Minnesota (US)
- From the Department of Pediatrics, Paracelsus Medical University, Salzburg, Austria (D.W.); the Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom (T.B.); the Division of Pediatric Endocrinology, Hospital Ángeles Puebla, Puebla City, Mexico (M.B.-P.); the Department of Pediatrics, Division of Pediatric Endocrinology, Universitair Ziekenhuis Brussel, Brussels (I.G.); Novo Nordisk, Søborg, Denmark (D.H., O.K.J., R.S.); the Department of Pediatrics and the Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis (A.S.K.); the Division of Pediatric Endocrinology and Diabetes, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY (L.D.M.); and the Center for Pediatric Research in Obesity and Metabolism, Division of Pediatric Endocrinology, Diabetes, and Metabolism, University of Pittsburgh School of Medicine, and UPMC Children’s Hospital of Pittsburgh, Pittsburgh (S.A.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-12-15
- Volume
- 387
- Issue
- 24
- Pages
- 2245-2257
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC9997064
- OpenAlex
- W4308053954
- Cited by
- 730
- References
- 26
- Citations by year
- 2026: 217 · 2025: 199 · 2024: 189 · 2023: 120 · 2022: 5
- FWCI
- 76.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion)
- PubMed Central (acceptedVersion)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- Digital Access to Libraries (submittedVersion, other-oa)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- semaglutide, adolescents, adolescent obesity, overweight, GLP-1 receptor agonists, weight loss, body mass index, cardiometabolic risk factors, lifestyle intervention, gastrointestinal adverse effects, gallstones, drug safety, weight-related comorbidities, HbA1c, alanine aminotransferase, waist circumference, serum lipids, serious adverse events
- MeSH terms
- Healthy Lifestyle, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Administration, Cutaneous, Adolescent, Child, Double-Blind Method, Humans, Weight Loss, Body Mass Index, Anti-Obesity Agents, Pediatric Obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
